Laurent Pradier

USPTO Granted Patents = 12 (Patent Applications = 2)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 43(Granted Patents)

Location History:

Verriéres, FR (2013)
Paris, FR (2013 - 2016)
Verrieres, FR (2003 - 2018)

Company Filing History:

Institut National De La Sante Et De La Recherche Medicale

patents

5. 1 out of 1,828

Sanofi-a Ventis Deutschland Gmbh

where one patent can have more than one assignee

Years Active: 2003-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10112991 - Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide (2018-10-30),

2. 9382312 - Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide (2016-07-05),

3. 9364519 - Pharmaceutical composition for use in the treatment of a neurodegenerative disease (2016-06-14),

4. 8614299 - Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide (2013-12-24),

5. 8492610 - Transgeneic animal expressing a multiple mutated form of presenilin 1 (2013-07-23),

6. 8343493 - Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs (2013-01-01),

7. 8273548 - Nucleic acids encoding a human PAP1 polypeptide (2012-09-25),

8. 7803538 - Method for detecting Alzheimer's disease (2010-09-28),

9. 7700823 - Transgenic animals exhibiting major disorders related to Alzheimer's disease (2010-04-20),

10. 7132396 - Compositions which can be used for regulating the activity of parkin (2006-11-07),

11. 7070940 - Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein (2006-07-04),

12. 6653088 - Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the &bgr;-amyloid peptide (2003-11-25),

Title: The Innovative Journey of Laurent Pradier in Alzheimer's Research

Introduction

Laurent Pradier, an accomplished inventor based in Verrieres, France, has contributed significantly to the field of biotechnology through his groundbreaking inventions. With a total of 12 patents to his name, Pradier's work focuses primarily on the development of humanized antibodies aimed at combating Alzheimer's disease.

Latest Patents

Among his latest patents are innovations related to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide. These antibodies are instrumental in advancing the understanding and treatment of Alzheimer's disease. The patents outline methods of utilizing these antibodies to target and mitigate the effects of the disease, showcasing Pradier's commitment to addressing one of the most pressing health challenges facing society today.

Career Highlights

Pradier has had an illustrious career, having worked with prominent companies in the pharmaceutical industry, including Aventis Pharma S.A. and Sanofi. His experiences at these institutions have greatly enriched his expertise in developing innovative solutions for complex medical issues.

Collaborations

Throughout his career, Pradier has collaborated with notable individuals in the field, such as Nicolas Baurin and Francis Blanche. These partnerships have facilitated the exchange of ideas and played a crucial role in the success of his research endeavors.

Conclusion

Laurent Pradier's contributions to biotechnology, particularly in the realm of Alzheimer's treatment, exemplify the impact of innovation in medicine. His ongoing research and development of humanized antibodies not only highlight his inventive spirit but also pave the way for future breakthroughs in the fight against this debilitating disease. With a solid foundation of patents and collaborations, he continues to inspire the next generation of inventors and researchers in the field.

This text is generated by artificial intelligence and may not be accurate.